F. Quhill and A. Beiderbeck, “Cost Advantage of Fluocinolone Acetonide Implant (ILUVIEN®) versus Ranibizumab in the Treatment of Chronic Diabetic Macular Oedema”, Grhta, vol. 4, no. 1, pp. 155–164, Jul. 2017.